Dutch medtech company TrianecT has raised €1.35m to bring its ambulance-based stroke detection device, StrokePointer, to market.
The portable system allows paramedics to assess stroke severity on scene and direct patients to centres equipped for specialist treatment.
Stroke affects one in four people over 25 and accounts for a third of global healthcare costs.
More than 50 per cent of patients with large vessel occlusion (LVO) strokes – where major arteries in the brain are blocked – are still taken to hospitals that lack the facilities needed for endovascular treatment.
This often leads to secondary transfers, delaying time-sensitive interventions by around an hour. In stroke care, every minute is vital as brain tissue rapidly deteriorates without oxygen.
StrokePointer uses EEG (electroencephalogram) technology to monitor brain activity, helping ambulance teams determine which patients should go to a specialist centre, rather than a standard stroke unit.
Wouter Potters, CEO and co-founder, said: “Thanks to this investment, and the strategic involvement of our new partners, we can accelerate the translation of our technology from scientific breakthrough to real-world application.
“This will ensure every stroke patient receives faster and better care.”
TrianecT was founded in September 2022 by neurologist Jonathan Coutinho, technical physician Wouter Potters and Professor Henk Marquering from Amsterdam UMC, together with AMC Ventures and German-based Neuromotion Ventures.
The €1.35m round was led by XO Ventures and CbusineZ and will fund the device’s commercial development and market introduction.
Karel Stolper, board member of CbusineZ, said: “This innovation fits perfectly with our mission to make healthcare more efficient and patient-centred.
“StrokePointer enables faster triage, in the right place and at the right time.”
